<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>24 Radiation protection issues when imaging patients for radiotherapy</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part29.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part31.htm">Далее &gt;</a></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="#bookmark30" class="s17" name="bookmark79">Chapter 24</a><a name="bookmark80">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_393.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark30" class="h2">Radiation protection issues when imaging </a><h2 href="#bookmark30">patients</h2></p><p style="padding-left: 55pt;text-indent: 0pt;text-align: left;"><h2 href="#bookmark30">for radiotherapy</h2></p><p class="s18" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;text-align: left;">simon thomas</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-top: 13pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">24.1 <span class="h4">Introduction</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The purpose of this chapter is to discuss the radiation protection implications of imaging with ionizing radiation, for patients who require such imaging as part of their radiotherapy pathway. This chapter will not consider forms of imaging, such as ultrasound (US) or magnetic resonance imaging (MRI) that do not involve ionizing radiation.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">This chapter will discuss the effects of ionizing radiation on the human body. It will give guidance on radiation dosimetry, on the regulations surrounding the use of ion- izing radiation, and on how to estimate the risks from ionizing radiation.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">24.2 <span class="h4">The effects of ionizing radiation on the body</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Imaging is performed pretreatment (for diagnosis, staging, and treatment planning), and during treatment (for verification and image guidance). All of this adds to the radiation received by normal tissues. In most cases this radiation will be considerably less than that received from the therapy doses.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">When considering the effects of radiation on the body, it is useful to distinguish be- tween deterministic effects and stochastic effects.</p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">A deterministic effect, which will occur at high dose levels (typically tens of Gy), is an event that is predicted to occur when a dose above a certain level is given. Radiotherapy treatment planning is largely concerned with achieving the deter- ministic effect of killing the tumour, whilst avoiding unwanted deterministic effects in organs at risk (OAR).</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">A stochastic effect, otherwise known as a probabilistic effect, is one that has a prob- ability of occurring, with the probability increasing with dose. Examples of such an effect are the risk of inducing cancer, and the risk of inducing heritable effects.</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The doses used for imaging are usually way below the threshold for deterministic ef- fects, so considerations of the risks from imaging concentrate on the stochastic ef- fects. The International Commission on Radiological Protection (ICRP) publishes guidelines on the risks of radiation to the human body; these serve as the basis for</p><p style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">national regulations and guidance.<span class="s22">1,2 </span>The data for stochastic effects are based on data from atomic bomb survivors and on epidemiological studies. Since it is hard to un- tangle effects for low doses from the underlying variations in non-radiation induced cancers, the data in practice are extrapolated to low doses from results at higher doses than usually seen in imaging, making an assumption that the graph of risk against dose follows a straight line through the origin. This assumption, known as the ‘linear non-threshold’ (LNT) model is not universally accepted; however, it forms the basis of ICRP’s recommendations, and will be followed in this chapter.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The risk of fatal cancer induction varies with age and sex, and there is a latent period (5–40 years) from irradiation to clinical presentation. For whole body doses of X-rays, the data shows a risk of approximately 5% per Gy for adults. Most imaging only irradiates part of the body; in this case the risk depends on which organs are irradiated. Methods for calculating this are discussed in the next section. It should be noted that for OAR from the radiotherapy dose, both stochastic and deterministic models can be used. The QUANTEC report<span class="s22">3 </span>gives thresholds for some toxicities (de- terministic), but also gives Normal Tissue Complication Probabilities (stochastic) for other toxicities.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">24.3 <span class="h4">Absorbed dose, equivalent dose, and effective dose</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The SI unit of Absorbed Dose is the Gray (Gy) equal to one joule per kilogram. Although this is a unit of appropriate size for considering radiotherapy doses, it is too large a unit for typical imaging doses, which are usually of a scale where the mGy (equal to one thousandth of a Gy) is the suitable unit.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Equivalent dose is a concept used to allow for the fact that different types of radi- ation, such as protons and alpha particles, cause greater damage for a given absorbed dose than do photons or electrons. Equivalent dose is defined as the absorbed dose multiplied by a radiation weighting factor. However, for electrons and for photons this weighting factor is equal to one, so for nearly all the imaging considered in this chapter equivalent dose is identical to absorbed dose.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Since different organs have different sensitivity to radiation, and many scenarios in which people are irradiated (including most imaging) involve irradiating only part of the body, the ICRP introduced the concept of effective dose. The effective dose is the dose to the whole body that would incur the same risk as a partial exposure of the body, when specific tissues receive an equivalent dose of H<span class="s36">T</span>:</p><p class="s34" style="padding-top: 3pt;padding-left: 90pt;text-indent: 0pt;text-align: center;"><span class="s31">E </span><span class="s32"></span><span class="s33"> </span><span class="s32"></span>T <span class="s35">w</span>T<span class="s35">H</span>T</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 89%;text-align: justify;">where w<span class="s36">T </span>is the weighting factor for the specific tissue. The sum is performed over all organs and tissues of the body considered to be sensitive to the induction of stochastic effects. The value given to w<span class="s36">T </span>reflects the radiation sensitivity of the tissue; it is, how- ever, averaged over both sexes and all ages. The value of effective dose calculated using these average weighting factors therefore does not represent the characteristics of a particular individual.</p><p style="padding-left: 14pt;text-indent: 0pt;line-height: 14pt;text-align: justify;">The most recent values of w<span class="s36">T, </span>published in ICRP Publication 103, are in Table 24.1.</p><p class="s24" style="padding-top: 6pt;padding-left: 65pt;text-indent: 0pt;text-align: left;">Table 24.1 <span class="s25">iCrp 103 tissue weighting factors</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:65.2305pt" cellspacing="0"><tr style="height:14pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Tissue</p></td><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">w<span class="s136">T</span></p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">Sum of w<span class="s136">T</span></p></td></tr><tr style="height:57pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 20pt;text-indent: 0pt;line-height: 112%;text-align: left;">Bone marrow Colon</p><p class="s27" style="padding-right: 38pt;text-indent: 0pt;line-height: 112%;text-align: left;">Lung stomach Breast</p></td><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">0.12</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">0.60</p></td></tr><tr style="height:15pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Gonads</p></td><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">0.08</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">0.08</p></td></tr><tr style="height:47pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 37pt;text-indent: 0pt;line-height: 112%;text-align: left;">Bladder oesophagus Liver thyroid</p></td><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">0.04</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">0.16</p></td></tr><tr style="height:47pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 35pt;text-indent: 0pt;line-height: 112%;text-align: left;">Bone surface Brain</p><p class="s27" style="padding-right: 20pt;text-indent: 0pt;line-height: 112%;text-align: left;">salivary glands skin</p></td><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">0.01</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">0.04</p></td></tr><tr style="height:15pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">remainder organs*</p></td><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">0.12</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">0.12</p></td></tr><tr style="height:15pt"><td style="width:80pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:54pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">total</p></td><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 31pt;padding-right: 34pt;text-indent: 0pt;text-align: center;">1.00</p></td></tr></table><p class="s21" style="padding-top: 1pt;padding-left: 65pt;text-indent: 0pt;line-height: 111%;text-align: left;">*remainder tissues: adrenals, extrathoracic (et) region, gall bladder, heart, kidneys, lymphatic nodes, muscle, oral mucosa, pancreas, prostate<span class="s15">♂</span>, small intestine, spleen, thymus, uterus/cervix<span class="s15">♀</span>.</p><p class="s21" style="padding-top: 2pt;padding-left: 65pt;text-indent: 0pt;line-height: 111%;text-align: left;">Adapted with permission from Crp, ‘iCrp103: the 2007 recommendations of the international Commission on radiological protection,’ <i>Ann. ICRP</i>, Vol. 37, pp. 2–4.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 12pt;text-align: justify;">The w<span class="s36">T </span>for the remainder tissue applies to the arithmetic mean dose of the 13 tissues for each sex. Effective dose is measured in sievert (Sv) rather than Gy. For an irradiation of the whole body, the effective dose and the absorbed dose are the same. In any practical imaging example, the effective dose (in mSv) will be less than the absorbed dose (in mGy). Strictly speaking, equivalent dose is also quoted in Sv. However, since we are considering only X-rays and electrons, we will ignore equivalent dose in the rest of this chapter, and regard the w<span class="s36">T </span>as factors to convert absorbed dose (in mGy) to effective dose (in mSv).</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">It has become common practice to use effective dose when considering radiation risks from diagnostic radiology where doses are relatively low and only stochastic ef- fects are being considered. All the values of E given in this chapter are calculated using ICRP 103 weighting factors. The uncertainties of the value of E are large (± 40%) even for a reference patient and will be much greater for the individual. Bearing in mind the above limitations of the averaging process in calculating E, the use of E does allow for comparisons of dose between different X-ray examinations, provided that a similar patient sample is considered.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">24.4 <span class="h4">Radiation protection legislation</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: left;">The relevant legislation in England, Wales and Scotland is the Ionising Radiation (Medical Exposure) Regulations 2017<span class="s22">4 </span>(in Northern Ireland, essentially the same</p><p style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">regulations are the Ionising Radiation (Medical Exposure) Regulations (Northern Ireland) 2018). This legislation implements a European obligation, set out in European Council Directive 2013/59/EURATOM.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">24.4.1 <span class="s124">Ionising radiation (medical exposure) regulations (IRMER 2017)</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">IRMER 2017 lays down measures to protect patients and others undergoing med- ical exposures from unnecessary radiation. The ICRP principles of justification and optimization are incorporated into the regulations. Dose limits are not applicable to patient procedures, but the benefit to the patient (or society through research) must outweigh any detriment from exposure to radiation for the exposure to be justified.</p><p style="padding-left: 14pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">Applied to radiotherapy the scope of the IRMER is to justify and optimize:</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">◆ <span class="p">The exposure of patients as part of their own medical diagnosis or treatment.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">The exposure of patients or other persons voluntarily participating in medical or biomedical, diagnostic, or therapeutic research programmes.</span></p><p class="s28" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">24.4.1.1 <span class="s66">Duty holders</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Regulation 2 of this legislation defines the roles of duty holders as:</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">◆ <span class="p">The employer, the referrer, the practitioner, the operator, and the MPE.</span></p><p class="s28" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">24.4.1.2 <span class="s66">The employer</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The employer as defined in this legislation is ‘any person who, in the course of a trade, business or other undertaking, carries out (other than as an employee), or en- gages others to carry out . . . exposures . . . or practical aspects, at a given radiological installation.’</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The employer as a duty holder under IRMER is responsible for providing a frame- work for radiation protection for patients. This framework is based on a minimum set of written procedures the ‘Employer’s Procedures’ (EPs) (these are set out in regulation 6(1) and schedule 2 of the legislation), written protocols, and quality assurance pro- grammes (Reg. 4).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A procedure must be in place to identify individuals who are entitled to act as re- ferrers, practitioners, or operators and the scope of practices for duty holders must be clearly identified and documented.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The employer has a responsibility to ensure that all entitled practitioners and op- erators are adequately trained to perform their tasks in their defined scope of prac- tice. A list of topics that training must cover is given in schedule 2 of the regulations, but training at local level on specific equipment, procedures, and protocols is also required. The training underpins the entitlement of the individual to act as a practi- tioner or operator for the range of practices for which they have been deemed com- petent. The employer must keep a record of all training and make it available for inspection.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The employer must also establish recommendations concerning referral criteria, including radiation doses, for medical exposures and make these available to the referrer.</p><p class="s28" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">24.4.1.3 <span class="s66">The referrer</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The referrer means a registered healthcare professional who is entitled in accordance with the employer’s procedures to refer individuals for exposure to a practitioner. The referrer must supply the practitioner with sufficient medical data (such as previous diagnostic information or medical records) relevant to the exposure requested by the referrer to enable the practitioner to decide whether there is a sufficient net benefit to justify the exposure.</p><p class="s28" style="padding-top: 8pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">24.4.1.4 <span class="s66">The IRMER practitioner</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The IRMER practitioner’s primary responsibility is to ensure that the requested med- ical exposure is justified. For an exposure to be justified, it must show sufficient net benefit, taking into account the total potential diagnostic or therapeutic benefits (both the direct benefits to the individual and the benefits to society), and the individual det- riment that the exposure may cause. The regulations list a number of factors that need to be taken into account, including cases involving comforters and carers, and health screening of asymptomatic individuals.</p><p class="s28" style="padding-top: 8pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">24.4.1.5 <span class="s66">The operator</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The operator is any person who carries out any practical aspect of the medical ex- posure. The operator and practitioner must together ensure that the doses arising from the exposure are kept as low as reasonably practicable, consistent with the intended purpose. Every exposure must be ‘authorized’. This authorization is pri- marily the responsibility of the practitioner, but in many practical cases for routine uses of radiation this is not practicable. Regulation 11(5) allows in these cases for the operator to authorize an exposure, in accordance with guidelines issued by the practitioner.</p><p class="s28" style="padding-top: 8pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">24.4.1.6 <span class="s66">Medical physics expert</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The medical physics expert (MPE) Reg. 14 (1) is defined as ‘an individual or a group of individuals, having the knowledge, training and experience to act or give advice on matters relating to radiation physics applied to exposure, whose competence in this respect is recognized by the Secretary of State.’ Anyone who was acting as an MPE prior to 31 December 2017 was able to be added to a list held at http://www.rpa2000. org.uk/, and to apply for transition to the formal register. Those not on the original list can apply to RPA2000 by submitting a portfolio of evidence showing they meet the requirements of the syllabus published on the RPA2000 web site.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The employer is required to ensure that a suitable MPE is appointed. They are re- quired to be ‘closely involved’ in every radiotherapeutic practice, and to be ‘involved’ or ‘involved as appropriate for consultation on optimization’ in other radiological practices. IRMER lists a number of areas on which an MPE must give advice; within radiotherapy physics these largely match the areas in which physicists are routinely involved.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A member of staff may have the role of more than one duty holder if the Employer’s Procedures entitle them to do so. For example the oncologist may be both the referrer and the practitioner.</p><p class="s28" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">24.4.2 <span class="s124">Diagnostic reference levels</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Patient diagnostic examinations are not subject to dose limits but the IRMER legis- lation requires that diagnostic reference levels (DRLs) be set for diagnostic examin- ations. The values are for the relevant dose indicator for a specific examination for a standard size patient.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The regulations require the employer to review, and make available to an operator, diagnostic reference levels; regard must be had to European and National DRLs where available.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 89%;text-align: justify;">National DRLs are in place in terms of entrance skin dose (ESD) (mGy) for indi- vidual radiographs and dose area product (DAP) (Gy.cm<span class="s22">2</span>) for more complex exam- inations. For CT exams the DRL is given in terms of CT dose index (CTDI<span class="s36">vol</span>) or dose length product (DLP).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The concept of DRLs applies only to diagnostic imaging, and is therefore not a legal requirement for radiotherapy planning images, or IGRT images. An IPEM working party is developing reference levels for radiotherapy imaging. A recently published report proposes national dose reference levels and ‘achievable levels’ of CT dose index (CTDI<span class="s36">vol</span>), dose-length-product (DLP), and scan length.<span class="s22">5 </span>These levels are proposed</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">based on the third quartile and median values of results from a UK-wide survey of CT</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">scanners used for radiotherapy treatment planning.</p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 8pt;line-height: 82%;text-align: justify;">The proposed dose reference levels for CTDI<span class="s36">vol </span>and DLP are: prostate 16 mGy and 570 mGy.cm, gynaecological 16 mGy and 610 mGy.cm, breast 10 mGy and 390 mGy.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">cm, 3D-lung 14 mGy and 550 mGy.cm, 4D-lung 63 mGy and 1750 mGy.cm, brain 50 mGy and 1500 mGy.cm, and head/neck 49 mGy and 2150 mGy.cm. The working party will also be reporting on IGRT imaging doses.</p><p class="s28" style="padding-top: 11pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">24.4.3 <span class="s124">Issues concerning pregnancy status (Reg. 11(1f) and 12(8d))</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">IRMER requires, in the case of an individual of childbearing potential, that the person carrying out the exposure has enquired whether the individual is pregnant (or breast- feeding if relevant). It is recognized that diagnostic dose levels are very much lower than those given to the patient during radiotherapy, but checking for pregnancy will be made first at the diagnostic stage for each individual patient. At diagnostic dose levels the only adverse effect of radiation on the unborn child which is likely to pose a risk is that of cancer induction. The implementation of official recommendations is discussed in the next paragraph.<span class="s22">6 </span>The procedure will apply to 12–55-year-old women; the RCR has discussed the problems associated with asking teenage girls about pregnancy. It is possible, though rare, that the practitioner may proceed with radiotherapy even if the patient is found to be pregnant, in which case the MPE will be asked to make a very careful estimate of risk to the unborn child.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In the diagnostic department (X-ray, nuclear medicine, or positron emission tom- ography (PET) or PET/computed tomography (CT)), the referrer ascertains the preg- nancy status and the operator confirms this before carrying out the exposure. If the patient is pregnant, the examination may still continue, provided further justification takes place that indicates the exposure is of net benefit. This must be documented.</p><p style="padding-top: 5pt;padding-left: 19pt;text-indent: 0pt;text-align: justify;">In the radiotherapy department the procedure will include the following:</p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">It is the referrer’s responsibility to ensure whether the patient may be pregnant and that the patient is informed about the risks of becoming pregnant (particularly if the patient is going to proceed to radiotherapy treatment).</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">The IRMER practitioner (consultant oncologist) will reassess the pregnancy status before prescribing the RT treatment.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">The operator’s responsibilities will include, ensuring that the patient has signed a declaration they are not pregnant and informing them that they must tell a radi- ographer before any ionizing radiation procedure that they may be pregnant. This declaration can conveniently be incorporated into the consent form used to give informed consent to treatment.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s28" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">24.4.4 <span class="s124">Special treatment of infants, children, and young adults</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The process of justification and optimization is particularly important for infants and young children since the risk of inducing a cancer is higher. This is due partly to the increased sensitivity to radiation of bone marrow in children and for young girls the developing breast tissue. Exposure protocols used for imaging should be specific to paediatrics; this is particularly important for CT scanning where the use of techniques used for adults can lead to unnecessarily high doses. Details of the increased risk of breast cancer induction with decreasing age can be found in the BEIR VII report<span class="s22">7 </span>and NHSBSP report 54.<span class="s22">8</span></p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">24.4.5 <span class="s124">Reporting of incidents</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Employers are obliged under regulation 8 to investigate where an incident has oc- curred or may have occurred involving a clinically significant unintended or ac- cidental exposure. This includes both those incidents that are significantly greater than ‘those generally considered to be proportionate’, and those that are signifi- cantly lower. Guidance on what is “significant” is available on the CQC website<span class="s22">9</span>, whilst guidance on what is “clinically significant” is available from the Radiotherapy Board<span class="s22">10</span>.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">If the investigation shows that such an exposure has occurred then the appro- priate authority (in England this is Care Quality Commission (CQC); in Wales, National Assembly for Wales: Health and Social Division, for Northern Ireland the NI Department of Health, and in Scotland, Scottish Ministers: Scottish Executive Health Department) must be notified and the employer must arrange for a detailed investi- gation of the circumstances of the exposure and an assessment of the dose received.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">24.4.6 <span class="s124">Quality assurance</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In order to maintain standards within the imaging departments and the radiotherapy department it is vital to have a quality assurance programme. This will cover all aspects of the work, staffing, and equipment within each department and will ensure that IRMER matters are covered (equipment QA is under IRR2017).<span class="s22">11</span></p><p style="padding-top: 6pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Patient dose audit—it is vital that the entire procedure for a particular examin- ation is checked routinely and that the dose given by each procedure is in line with the national guidelines. Employer’s Procedures must be regularly reviewed; it should be documented how this is done, and which individual is responsible for the review being done.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Senior management must take responsibility for ensuring that procedures are re- viewed at a sufficient frequency to take into account the impact of new technology and role development which will impact on ways of working.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">24.5 <span class="h4">The radiotherapy episode: justification and assessing patient dose</span></p><p class="s28" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">24.5.1 <span class="s124">Diagnostic and staging imaging before the commencement of RT</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A referral for imaging to diagnostic radiology is deemed to be a request for a profes- sional opinion, which the radiologist as practitioner will justify and authorize if s/ he thinks the exposure appropriate. Exposures which meet referral criteria, as drawn up by the radiology department, may not need individual justification; however, they need to be authorized by the person carrying out the exposure. Where imaging in- volves nuclear medicine or PET scanning the practitioner must be the ARSAC certifi- cate holder.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">24.5.2 <span class="s124">Planning CT images</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">It is simplest to consider doses incurred during planning as included in the radio- therapy prescription. The above exposures are requested by the oncologist (IRMER re- ferrer) in accordance with written and signed protocols drawn up by the lead specialist oncologist (IRMER practitioner). The protocols should be sufficiently flexible to allow for additional planning images but must not be open-ended. If exposures additional to those detailed in the protocol are required the exposures must be additionally justified and authorized. The protocols must be regularly reviewed.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">24.5.3 <span class="s124">Verification and IGRT imaging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These are the images taken during radiotherapy, either just before each treatment ex- posure is made or during the treatment exposure. They may be carried out at each fractionated treatment exposure, or less frequently in line with local protocols. Except for the exposures using the treatment field (such as MV portal imaging with no change of field size), all these verification and image guidance methods give additional dose to the patient. The treatment itself and the concomitant verification images (using portal imaging or CT as defined in the treatment protocol) will be justified by a consultant clinical oncologist.</p><p class="s28" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">24.5.4 <span class="s124">Justification and dose assessment</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Justification requires that the benefit and detriment of every exposure be considered, taking into account the intention of each exposure and the characteristics of the</p><p style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">individual patient. Any exposures performed outside of protocol must be justified separately (and a note made in the patient’s record). This consideration is not a simple task. The target volume must be planned optimally with as much information from the scans as possible in order to define the target and critical structures optimally. The radiotherapy delivery is checked regularly (both inter- and intrafraction), using verification imaging including the various forms of CT and cone beam CT (CBCT), to ensure that these volumes have been correctly covered or avoided respectively by the high radiation dose region. If this set of tasks is not performed optimally then the clinical oncologist is failing the radically treated patient. There is also a balance to be drawn for each patient between the potential for deterministic damage to critical structures and the risk of radiation-induced cancer. In addition, as delivery techniques become more complicated and treatment is tailored to inter/intrafractional organ movement more verification imaging will be required.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">To make a full risk assessment for the individual patient, it is necessary under</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">IRMER to understand all those doses associated with the various image procedures during a radiotherapy episode. For the diagnostic images this may be considered to be straightforward by using effective dose. For a fuller interpretation of all the doses re- ceived by the radiotherapy patient, including those doses to organs/critical structures outside the treatment volume, it will be necessary to approach the problem differently. The treatment doses to organs immediately surrounding the target volume can be very high, for example if the target dose is 70 Gy then even at levels of 1–10% the doses to surrounding organs may be 700–7000 mGy.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">To estimate the risk of inducing a cancer in these organs (or damaging non-tumour tissue) it is preferable to determine individual organ doses (the most heavily irradiated organs for a particular treatment site) from all the imaging and treatment received by the patient and then to attach a stochastic risk factor to that total organ dose. This is preferable to using effective dose, since effective dose combines together all ages and does not discriminate between the sexes. This is particularly important when con- sidering infants, children, and young adults in order to attribute the appropriate risk factor for cancer induction.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The main problem in performing such calculations is how to deal with imaging dose that covers the high dose area of the radiotherapy treatment, since cancer induction risk factors are modelled for doses where a linear response is assumed, and this is not the case at higher doses. Various models have been proposed<span class="s22">12 </span>ranging from ones that plateau at a certain dose, to ones that actually decrease at high doses (on the basis that cancers induced in the high dose region of the treatment will be immediately steril- ized by the treatment). There is currently no consensus on which model is correct. Calculating using several models can be useful if they all show one irradiation plan to be higher than another.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The other half of a risk calculation is to quantify the benefit that comes from image guidance. This is even harder, since evidence for the benefits of IGRT tends to be quali- tative rather than quantitative. The benefits of IGRT, in avoiding an underdose due to geographic miss, or in allowing smaller PTV margins (and hence sparing organs at risk) are hard to test in a randomized trial. The CHHIP-IGRT sub-study provides some evidence for daily IGRT<span class="s22">13</span>.</p><p style="padding-top: 6pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;"><a href="http://www.hra-decisiontools.org.uk/consent/docs/Generic%2520Radiation%2520Risk%2520Statements%2520IRAS%2520PIS%2520v3.5%25202018.02.27%2520-%2520Consultation%2520in%2520Use.pdf" class="s125" target="_blank">A risk calculation of cancer induction, even if using effective dose, is better than no calculation at all. At present the advice given by the Health Research Authority for MPEs performing risk calculations for clinical trials is to use generic risk statements such as: ‘We are all at risk of developing cancer during our lifetime. The normal risk is that this will happen to about 50% of people at some point in their life. Taking part in this study will increase the chances of this happening to you from 50% to [insert estimated risk] %.’ Further examples of risk statements are given at http://www.hra- decisiontools.org.uk/consent/docs/Generic-ionising-radiation-risk-statements_v4_ </a>October2020.pdf.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">24.5.5 <span class="s124">Examples of imaging exposures</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Methods for making these exposures include:</p><p class="s12" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;"><span class="s23">◆ </span>Megavoltage portal imaging<span class="p">. This is mainly now done using an electronic portal imaging device (EPID) attached to the gantry of the linear accelerator. Imaging is achieved either using the treatment field or using a radiation field larger than the treatment field, and often using an orthogonal pair of images. When most radio- therapy was given at fixed angles, with MLC shaped to conform to the PTV, this could be routinely used to image each field and every treatment. As rotational IMRT techniques such as VMAT take over, this has less value for geometric verifi- cation. However EPIDs have gained a new role in exit dosimetry, since they are one of the few devices that can be used for </span>in vivo <span class="p">dosimetry of VMAT.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="s12">Kilovoltage imaging</span><span class="p">. Most conventional linacs are now sold with a kilovoltage unit attached to the gantry; the X-ray set and imaging plate (digital) are mounted orthogonally to the megavoltage beam (for Varian and Elekta models). Other manufacturers (e.g. Accuray and BrainLab) install ceiling and floor mounted com- binations of X-ray sets and imaging plates. Either form of kilovoltage unit can be used for routine imaging of the radiotherapy patient.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="s12">Megavoltage CT</span><span class="p">. Helical tomotherapy units (Accuray Inc.) image with megavoltage spiral CT (the energy of the imaging beam is slightly lower than the treatment beam).</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="s12">Kilovoltage cone beam CT (CBCT)</span><span class="p">. When a kV set is mounted on the linac gantry (Varian and Elekta) it can be used to take CT images with cone beam; a volume CT is achieved by using the cone beam and rotating the gantry through 360° in 1 min.</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In order to illustrate the above points a few examples have been taken from the various examinations required for the following tumour sites: prostate, breast, and lymphoma (Tables 24.2, 24.3, and 24.4). The list of examinations is included in these tables, to- gether with various illustrative doses—effective dose; CTDI; isocentric dose (which gives a typical value of dose in the central region of the examination for organs close to this region,); and a dose to the most critical organ.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The values given in Tables 24.2, 24.3, and 24.4 are an indication only. These values will depend on the geometry of the equipment used, the technique factors selected, the volume of the patient irradiated, and the size of the patient. The value of effective dose from a CT scan is also very dependent on the image length scanned, the image quality required, and the pitch of the scan (couch movement per rotation/X-ray beam</p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: justify;">Table 24.2A <span class="s25">prostate patient with the approximate dose per examination</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3387pt" cellspacing="0"><tr style="height:35pt"><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Examination</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">E (mSv)</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 4pt;padding-right: 3pt;text-indent: 0pt;line-height: 112%;text-align: left;">Typical CTDI (mGy)</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 112%;text-align: left;">Typical isocentre dose (mGy)</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 4pt;text-indent: 0pt;line-height: 112%;text-align: left;">Bladder dose (mGy)</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">% of bladder included</p></td></tr><tr style="height:15pt"><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Pre-treatment images</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Ct (kV)</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">10</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">22</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">11</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">21</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">100</p></td></tr><tr style="height:26pt"><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 22pt;text-indent: 0pt;line-height: 112%;text-align: left;">diagnostic pet (400 mBq FdG)</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">11</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">nA</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">nA</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">68</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">100</p></td></tr><tr style="height:15pt"><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Verification images</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:26pt"><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">tomotherapy image (3mV)</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">0.6</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">11</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">11</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">50</p></td></tr><tr style="height:15pt"><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">CBCt (kV)</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">6</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">30</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">30</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">50</p></td></tr><tr style="height:26pt"><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">CBCt (kV), low mAs for use with seeds</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">0.8</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">4</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">4</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">50</p></td></tr><tr style="height:26pt"><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">portal imaging, using wide fields</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">1</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">2</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">2</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">100</p></td></tr><tr style="height:26pt"><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">portal imaging using treatment beam</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">0</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">0</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">0</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">0</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">nA</p></td></tr><tr style="height:15pt"><td style="width:86pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">portal kV image</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">0.1</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">1</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">0.2</p></td><td style="width:48pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">0.4</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">100</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">width). If CT is used in an over sampling mode (pitch 0.1) to remove motion blurring and to define movement related margins (e.g. for 4D CT imaging of the lungs) there is a possibility that a dose 5–10 times the conventional CT dose may be given. The med- ical physics expert in a cancer centre will be able to provide more specific doses for a particular equipment and image technique.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A number of verification imaging regimens have been considered for each treatment site, to indicate the variation of effective and critical organ doses with imaging mo- dality and frequency of imaging. These doses have been multiplied by the relevant risk factor to give a possible induced fatal cancer risk (lifetime) expressed as a percentage.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_394.png"/></span></p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Table 24.2B <span class="s25">prostate patient. the approximate dose and risk per imaging regime (assume 20# treatment)</span></p><p class="s39" style="padding-top: 8pt;padding-left: 11pt;text-indent: 0pt;line-height: 112%;text-align: left;">Protocol: verification imaging only</p><p class="s39" style="padding-top: 8pt;padding-left: 11pt;text-indent: 0pt;line-height: 112%;text-align: left;">Typical E (mSv)</p><p class="s39" style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;line-height: 112%;text-align: left;">% Risk of fatal cancer (rf of 5%/Sv)</p><p class="s39" style="padding-top: 8pt;padding-left: 3pt;text-indent: 0pt;line-height: 112%;text-align: left;">Critical organ: bladder dose x (mGy)</p><p class="s39" style="padding-top: 8pt;padding-left: 3pt;text-indent: 0pt;line-height: 112%;text-align: justify;">% Risk of fatal bladder cancer (rf of 0.12%/Gy)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_395.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">1) daily mVCt imaging (tomo)   12    0.06     220 (to 50%)  0.013</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_396.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">2) CBCt kV           120    0.6      600 (to 50%)  0.036</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_397.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">3) CBCt kV with seeds      16    0.08     80 (to 50%)  0.005</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_398.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">4)1# CBCt + 20# kV planar pairs 4.8    0.02     16 (to 100%)  0.002</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_399.png"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 24pt;text-indent: 0pt;text-align: left;">Table 24.3A <span class="s25">Breast patient with the approximate dose per examination</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:24.3642pt" cellspacing="0"><tr style="height:35pt"><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Examination</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Typical E (mSv)</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 5pt;padding-right: 6pt;text-indent: 0pt;line-height: 112%;text-align: justify;">Critical organ contralateral breast mGy</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 6pt;text-indent: 0pt;text-align: left;">Lung mGy</p></td></tr><tr style="height:15pt"><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Pre-treatment images</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">mammogram</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">0.3</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">0</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">0</p></td></tr><tr style="height:15pt"><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Ct (kV) full chest</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">6</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">9</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">15</p></td></tr><tr style="height:15pt"><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Verification images</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">CBCt (6mV)</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">10</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">20</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">30</p></td></tr><tr style="height:26pt"><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">Lat portal imaging with treatment field</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">0.0</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">0.0</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">0.0</p></td></tr><tr style="height:26pt"><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 4pt;text-indent: 0pt;line-height: 112%;text-align: left;">Lat portal imaging with 2 mu non-treatment field</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">1.2</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">3.3</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">5.4</p></td></tr><tr style="height:15pt"><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Lat portal imaging kV/image</p></td><td style="width:68pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">0.04</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">0.15</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">0.1</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 8pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A risk factor (rf) of 5% per Sv has been taken from ICRP 103<span class="s22">2 </span>to estimate the number of fatal cancers induced when adults (aged 18–64 years) are irradiated with an effective dose of E mSv.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A few examples of risk calculations have been given here, but it must be recognized that this is a developing subject.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Risk factors for inducing a cancer in an individual organ for adults have been taken from ICRP 103. The risk factors used are for irradiated adults aged 18–64, are gender specific, and are for the product of risk coefficient and lethality factor.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For lymphoma the values given in Table 24.4 are approximate but have been in- cluded because of potential risks to young patients. For example, PET/CT has become an issue with ethical committees for young people involved in clinical trials since mul- tiple scans are given. However, in general this additional imaging dose may be more than offset by the reduction in radiotherapy dose with the use of involved fields instead of mantle fields. The evidence of second cancer risk for these patients is dramatic. Most</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 24.3B <span class="s25">Breast patient. Approximate dose and risk per imaging regime</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6929pt" cellspacing="0"><tr style="height:56pt"><td style="width:69pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;text-indent: 0pt;line-height: 112%;text-align: left;">Typical E (mSv)</p></td><td style="width:40pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;padding-right: 10pt;text-indent: 0pt;line-height: 112%;text-align: left;">% risk of fatal</p><p class="s26" style="padding-left: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">cancer (rf 5%/Sv)</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">Critical organ: contralateral breast (mGy)</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;padding-right: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">% risk of fatal cancer induction in breast (rf 0.34%/Gy)</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">Critical organ: lung (mGy)</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;padding-right: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">% risk of fatal cancer induction in lung (rf 1.55%/Gy)</p></td></tr><tr style="height:26pt"><td style="width:69pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">1) high (1 planning</p><p class="s27" style="padding-top: 1pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">Ct +15 CBCt)</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 20pt;text-indent: 0pt;text-align: right;">156</p></td><td style="width:40pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">0.78</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 35pt;text-indent: 0pt;text-align: right;">306</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 23pt;text-indent: 0pt;text-align: right;">0.10</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 14pt;text-indent: 0pt;text-align: right;">465</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">0.72</p></td></tr><tr style="height:36pt"><td style="width:69pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: -8pt;line-height: 112%;text-align: left;">2) Low (1 planning Ct + pi using treatment fields)</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 20pt;text-indent: 0pt;text-align: right;">6</p></td><td style="width:40pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">0.03</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 35pt;text-indent: 0pt;text-align: right;">6</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 23pt;text-indent: 0pt;text-align: right;">&lt;0.01</p></td><td style="width:31pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 15pt;text-indent: 0pt;text-align: right;">6</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">0.01</p></td></tr></table><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: justify;">Table 24.4A <span class="s25">Lymphoma (upper body), age ten years</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3387pt" cellspacing="0"><tr style="height:14pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Examination</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">E (mSv)</p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Critical organ</p></td><td style="width:129pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:24pt"><td style="width:96pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:47pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-right: 9pt;text-indent: 0pt;line-height: 112%;text-align: left;">Breast dose (mGy)</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 112%;text-align: left;">Red bone marrow dose (mGy)</p></td><td style="width:58pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 4pt;padding-right: 16pt;text-indent: 0pt;line-height: 112%;text-align: left;">Lung dose (mGy)</p></td></tr><tr style="height:15pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Pre-treatment images</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Bone scan 355mBq tc<span class="s87">99m</span></p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">5</p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">0</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">7</p></td><td style="width:58pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">0.9</p></td></tr><tr style="height:15pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">pet</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">13</p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">5</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">6</p></td><td style="width:58pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">6</p></td></tr><tr style="height:15pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">pet with Ct</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">17</p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 1pt;text-indent: 0pt;text-align: left;">22</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;text-align: left;">10</p></td><td style="width:58pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">18</p></td></tr><tr style="height:15pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Ct (kV)</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">4</p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 1pt;text-indent: 0pt;text-align: left;">17</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">4</p></td><td style="width:58pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">12</p></td></tr><tr style="height:26pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-right: 9pt;text-indent: 0pt;line-height: 112%;text-align: left;">simulator fluoroscopy for 1 min(Ap)</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">1.5</p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">7</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">0.5</p></td><td style="width:58pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">3.3</p></td></tr><tr style="height:15pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Verification images</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:15pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Ap portal kV/image</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">0.04</p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">0.15</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">0.01</p></td><td style="width:58pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">0.1</p></td></tr><tr style="height:15pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">Ap portal 6mV/image/mu</p></td><td style="width:47pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">2</p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 1pt;text-indent: 0pt;text-align: left;">10</p></td><td style="width:71pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 8pt;text-indent: 0pt;text-align: left;">0.5</p></td><td style="width:58pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">7</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">of the research work on this appears to demonstrate that the second cancers induced in breast and lung are in the margins and high-dose regions of these organs.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">24.6 <span class="h4">Discussion</span></p><p class="s28" style="padding-top: 8pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">24.6.1 <span class="s124">Prostate</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The effective dose from daily IGRT is strongly dependent on the technique and equip- ment used. The lowest doses will be given in centres that implant fiducial markers in the prostate, and use a treatment technique with static conformal fields. By imaging the seeds using the first few MU of each of the treatment fields, it is possible to do image guidance with no additional dose. Cone-beam CT doses can be considerably re- duced if fiducial seeds are used. However, the reduction in dose needs to be set against</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Table 24.4B <span class="s25">Lymphoma patient (upper body) aged ten. Approximate dose and risk per imaging regime</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3387pt" cellspacing="0"><tr style="height:22pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Protocol</p></td><td style="width:43pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 10pt;text-indent: 0pt;text-align: left;">E (mSv)</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-left: 6pt;padding-right: 1pt;text-indent: 0pt;line-height: 11pt;text-align: left;">% risk of fatal cancer</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-left: 5pt;padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Critical organ: breast dose</p></td><td style="width:69pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s26" style="padding-left: 4pt;padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: left;">% risk of cancer in breast</p></td></tr><tr style="height:13pt"><td style="width:96pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:43pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-left: 4pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">(rf 10%/Gy)</p></td><td style="width:60pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">(mGy)</p></td><td style="width:69pt;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">(rf 4.3%/Gy)</p></td></tr><tr style="height:23pt"><td style="width:96pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-left: 8pt;text-indent: -8pt;line-height: 11pt;text-align: left;">1) high (1 Ct + 20 portal pairs 6 mV of 1 mu +</p></td><td style="width:43pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">169</p></td><td style="width:55pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 4pt;padding-right: 3pt;text-indent: 0pt;text-align: center;">1.7</p></td><td style="width:60pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 33pt;text-indent: 0pt;text-align: left;">527</p></td><td style="width:69pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 14pt;text-indent: 0pt;text-align: left;">2.3</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_400.png"/></span></p><p class="s41" style="padding-left: 20pt;text-indent: 0pt;text-align: left;">5 pet with Ct)</p><p class="s41" style="padding-top: 5pt;padding-left: 20pt;text-indent: -8pt;line-height: 112%;text-align: left;">2) Ct based (1 Ct+ 10 kV portal pairs)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s41" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">4.4     0.04       20    0.1</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_401.png"/></span></p><p style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">the risks involved with seed insertion, and the cost of the seeds. Volumetric imaging techniques that allow the region imaged to be closely tailored to the target volume (such as TomoTherapy) can give lower effective doses than those that have standard length imaging beams.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s28" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">24.6.2 <span class="s124">Breast</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The use of CT for verification images leads to a higher contralateral breast dose than the use of a lateral portal image. The use of organ dose rather than effective dose gives a more detailed description of the cancer risk. For the regimes shown in Table 24.4B, the risk of cancer from the doses to lung alone is essentially the same as the nominal risk calculated from the effective dose.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s28" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">24.6.3 <span class="s124">Lymphoma</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The total imaging doses under the ‘high dose’ regimen above are significant. The breast doses (approximately 0.5 Gy) by themselves give a theoretical risk for second cancer of 2.3% (for a 10–15-year-old girl). It is interesting to compare this dose with the various levels used in modern radiotherapy for these patients. The rate of induction of lung and breast cancer in patients treated for Hodgkin disease, mainly with mantle fields, is now well understood.<span class="s22">14–15 </span>This risk should now be reduced by the use of involved fields where less of each critical structure is irradiated, so potentially reducing the impact of the increased imaging.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">24.7 <span class="h4">Summary</span></p><p class="s23" style="padding-top: 8pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Imaging in radiotherapy is very extensive and takes place throughout the patient journey, with images being taken for diagnosis, treatment planning, and verifica- tion of treatment.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">◆ <span class="p">The control of these imaging processes is governed by IRMER 2017.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">The doses received by the patient from pretreatment imaging are relatively small, the highest effective dose being from a PET with CT examination.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Verification and IGRT imaging doses are higher, but are still generally only a few per cent of the leakage and scatter dose. However, when frequent verification im- ages, particularly CT, are taken the dose can become comparable to the leakage and scatter dose.</span></p><p class="s137" style="padding-top: 1pt;padding-left: 27pt;text-indent: -10pt;line-height: 94%;text-align: justify;">● <span class="p">The critical organ typically receives a range of dose from scatter and leakage (depending how close it is to the PTV) of 1–90%.</span></p><p class="s137" style="padding-left: 27pt;text-indent: -10pt;line-height: 94%;text-align: justify;">● <span class="p">A typical imaging dose to this organ will be about 0.1%, although this could increase to 1%.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Imaging regimens need to be carefully reviewed in every radiotherapy department and this may be achieved by:</span></p><p class="s137" style="padding-top: 1pt;padding-left: 17pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">● <span class="p">Where possible using imaging techniques that do not involve ionizing radiation.</span></p><p class="s137" style="padding-left: 17pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">● <span class="p">Reducing the field of view of the image to the smallest required.</span></p><p class="s137" style="padding-top: 6pt;padding-left: 33pt;text-indent: -10pt;line-height: 94%;text-align: justify;">● <span class="p">Using image technique factors that are commensurate with the image quality required for treatment decisions to be made.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">It is vital to give special consideration to children and young adults who are ex- posed to radiation. This group of patients has a longer period of time over which they may express a radiation induced cancer and they may have more exposures to radiation during that period. It will be of great value to these patients, and the scientific community, to keep records of all these exposures for each individual.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">When considering risk to the individual patient the use of effective dose and a gen- eral risk factor of 5% per Sv for cancer induction may underestimate the risk. This is particularly true when the breast area is irradiated. The evidence for induction of radiation-induced cancer is sparse but suggests that the second cancers appear in the high-dose regions around the treatment area. This is also the volume that re- ceives the verification imaging dose. Generally, the increase in dose due to this area from imaging is relatively low, but in the cases where frequent imaging, particularly (CT), is used these doses can become significant. However, the clinical oncologist has to weigh up all these issues for each patient when balancing the tumour control, morbidity, and second cancer risks.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Acknowledgements</p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: left;">Thanks go to the authors of the previous edition of this chapter, Jane Shekhdar and Edwin Aird. Much of their valuable contribution has been retained in this version.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s126" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">References</p><p class="s74" style="padding-top: 4pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">1. <b>ICRP </b>(1991). ICRP 60: Recommendations of the International Commission on Radiological Protection. <i>Annals of ICRP</i>, <b>21</b>: 1–3.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">2. <b>ICRP </b>(2007). ICRP103: The 2007 Recommendations of the International Commission on Radiological Protection. <i>Annals of ICRP</i>, <b>37</b>: 2–4.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">3. <b>Bentzen SM</b>, <b>Constine LS</b>, <b>Deasy JO, et al. </b>(2010). Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. <i>International Journal of Radiation Oncology</i>, <b>76</b>(3): S3–S9.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">4. <i>The Ionising Radiation (Medical Exposure) Regulations 2017 </i>(2017). Queen’s Printer of Acts of Parliament.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: justify;">5. <b>Wood TJ, Davis AT</b>, <b>Earley J</b>, <b>Edyvean S, et al. </b>(2018). IPEM topical report 2: the first UK survey of dose indices from radiotherapy treatment planning computed tomography scans for adult patients. <i>Physical Medicine Biology, </i><b>63</b>(18): 185008.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">6. <b>Health Protection Agency, Royal College of Radiologists, and College of Radiographers (2009). </b><i>Protection of pregnant patients during diagnostic medical exposures to ionising radiation: advice from the Health Protection Agency, the Royal College of Radiologists and the College of Radiographers</i>. UK: Health Protection Agency.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">7. <b>BEIR VII </b>(2006). <i>Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. </i>Washington, DC: The National Academies Press.</p><p class="s74" style="padding-top: 1pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">8. <b>NHSBSP </b>(2003). <i>Review of Radiation Risks in Breast Screening</i>. NHSBSP Publication No 54.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">9. <b>Care Quality Commission (2020). </b><a href="http://www.cqc.org.uk/" class="a" target="_blank">Significant accidental and unintended exposures under IR(ME)R. Version 2, August 2020. https:/www.cqc.org</a><a href="http://www.cqc.org.uk/" target="_blank">.uk</a></p><p class="s74" style="padding-top: 6pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">10. <b>Radiotherapy Board (2020). </b><a href="http://www.rcr.ac.uk/" class="a" target="_blank">Ionising Radiation (Medical Exposure) Regulations: Implications for clinical practice in radiotherapy. https://www.r</a>cr.ac.uk</p><p class="s74" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">11. <b>The Ionising Radiation Regulations 2017 (2017). </b>Queen’s Printer of Acts of Parliament.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">12. <b>Ruben JD, Davis S, Evans C, et al. (2008). </b>The effect of intensity- modulated radiotherapy on radiation- induced second malignancies. <i>International Journal of Radiation Oncology, </i><b>70</b>(5): 1530–1536.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">13. <b>Murray J, Griffin C, Gulliford S et al. (2020). </b>A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. <i>Radiotherapy and Oncology, </i><b>142</b>, 62–71.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">14. <b>Travis LB, Hill DA, Dores GM, et al. (2003). </b>Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. <i>Journal of American Medical Association, </i><b>290</b>(4): 465.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: justify;">15. <b>van Leeuwen FE, Klokman WJ, Veer MB, et al. </b>(2000). Long- term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. <i>Journal of Clinical Oncology, </i><b>18</b>(3): 487–497.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s126" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Further reading</p><p class="s74" style="padding-top: 5pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/720282/guidance-to-the-ionising-radiation-medical-exposure-regulations-2017.pdf" style=" color: #231F20; font-family:&quot;Palatino Linotype&quot;, serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 8.5pt;" target="_blank">The DHSC has published guidance to the regulations. </a><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/720282/guidance-to-the-ionising-radiation-medical-exposure-regulations-2017.pdf" class="a" target="_blank">https://assets.publishing.service.gov. uk/government/uploads/system/uploads/attachment_data/file/720282/guidance-to-the- </a>ionising-radiation-medical-exposure-regulations-2017.pdf This is not intended to be binding, but is a guide to help explain how the regulations should be interpreted.</p><p class="s75" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;">The Royal College of Radiologists, Society and College of Radiographers, Institute of Physics and Engineering in Medicine (2008). <i>A Guide to Understanding the Implications of the Ionising Radiation (Medical Exposure) Regulations in Radiotherapy</i><span class="s74">. London: The Royal College of Radiologists.</span></p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part29.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part31.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
